Skip to main content

Table 3 Comparison of frequency of patient characterisitcs between QFT-GIT positive vs. QFT-GIT negative

From: Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA

Variable

QFT-GIT positive (N = 66)

QFT-GIT negative (N = 427)

P value

Male gender

58 (87.9)

324 (75.9)

0.03

Age (Median (25th, 75th))

33 (23, 44)

31 (24, 42)

0.52

Age, by category

 18–29

28 (42.4)

201 (47.1)

0.54

 30–39

14 (21.2)

108 (25.3)

 

 40–49

15 (22.7)

72 (16.9)

 

  > 50

9 (13.6)

46 (10.8)

 

Hispanic ethnicity

21 (39.6)

97 (27.6)

0.07

Race

 Black

26 (39.4)

201 (47.1)

0.46

 White

20 (30.3)

121 (28.3)

 

 Other

20 (30.3)

105 (24.6)

 

Non US born

2 (3.1)

16 (3.8)

1.00

Stayed in homeless shelter

14 (21.2)

57 (13.4)

0.10

>1 incarceration

58 (89.2)

358 (84.2)

0.30

Ever Injected Drugs

16 (24.6)

60 (14.2)

0.03

HIV +

1 (1.5)

12 (2.8)

1.00

Tested for HIV in past

45 (68.2)

307 (71.9)

0.62

Ever treated for TB

3 (5.0)

2 (0.5)

0.02

Vaccinated with BCG

8 (14.3)

50 (14.1)

0.97

Ever been exposed to TB

4 (6.5)

11 (2.8)

0.14

TST read

47 (73.4)

304 (71.2)

0.71

TST > 5 mm

4 (8.5)

4 (1.3)

0.01

TST > 10 mm

2 (4.3)

3 (1.0)

0.14

TB symptoms

 Cough 3 weeks

1 (1.6)

1 (0.2)

0.24

 Hemoptysis

0 (0.0)

1 (0.2)

1.00

 Night sweats

1 (1.6)

3 (0.7)

0.43

 Unexplained weight loss

0 (0.0)

2 (0.5)

1.00

 Any of the above

1 (1.5)

6 (1.4)

1.00

  1. US United States of America, HIV human immunodeficiency virus, TB tuberculosis, BCG bacille Calmette-Guérin, TST tuberculin skin test